Jian-Gong Wang

Jian-Gong Wang

Auto-generated profile, based on publicly available information

Jian-Gong Wang

Department of Chemoradiotherapy, Tangshan People’s Hospital, Tangshan, Hebei Province, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YLYi‐Hui Li
Yi‐Hui Li
YZYang Zhou
Yang Zhou
YLYuan‐Yuan Liu
Yuan‐Yuan Liu
GZGuang‐Ju Zhang
Guang‐Ju Zhang
LXLei Xiao
Lei Xiao
LZLi Zhang
Li Zhang
Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune‐related adverse events (irAEs). Pneumonitis is an uncommon but potentially fatal irAE. In the case reported here, a patient with advanced small cell lung cancer (SCLC) had rapid progression of disease following chemotherapy and received ICIs. The patient experienced severe immune‐related hyperthermia followed by immune‐related pneumonitis. Fortunately, a good clinical response was achieved after the patient received corticosteroids and tocilizumab.

9 September 2022 in Medicine
Verified
Journal Article
Open access
YLYi-Hui Mmed Li
Yi-Hui Mmed Li
YZYang Zhou
Yang Zhou
GZGuang-Ju Mmed Zhang
Guang-Ju Mmed Zhang
YWYu-Wei Mmed Wang
Yu-Wei Mmed Wang
JWJIan-gong Wang
JIan-gong Wang
YLYufeng Li
Yufeng Li
Rationale: Vulvar melanoma is a rare and aggressive tumor with a high risk of local recurrence and distant metastasis. The prognosis is poor with a 5-year overall survival rate of only 46.6%. Management of vulvar melanoma remains a clinical challenge. Recent evidences have shown that immune checkpoint inhibitors are effective in the treatment of vulvar melanoma. Patient concerns and diagnoses: A 63-year-old woman with vulvar malignant melanoma suffered inguinal lymph node metastasis after vulvectomy and chemotherapy. She underwent inguinal lymph node dissection and inguinal radiotherapy. The tumor progressed again and she received immunotherapy. Interventions: The tumor progressed again, and she was admitted to our hospital and received toripalimab combined with apatinib and abraxane. Outcomes: After 6 cycles of immunotherapy, the efficacy achieved partial remission. And with toripalimab as maintenance therapy, the patient achieved durable antitumor efficacy and good safety. Lessons: In this rare case, the patient with metastatic vulvar malignant melanoma had durable antitumor efficacy and good safety when receiving toripalimab.